Lynn Huynh
About
Lynn Huynh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology.
According to data from OpenAlex, Lynn Huynh has authored 95 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 20 papers in Epidemiology. Recurrent topics in Lynn Huynh's work include Neuroendocrine Tumor Research Advances (13 papers), Neuroblastoma Research and Treatments (13 papers) and Eosinophilic Disorders and Syndromes (10 papers). Lynn Huynh is often cited by papers focused on Neuroendocrine Tumor Research Advances (13 papers), Neuroblastoma Research and Treatments (13 papers) and Eosinophilic Disorders and Syndromes (10 papers). Lynn Huynh collaborates with scholars based in United States, Canada and France. Lynn Huynh's co-authors include Paul Keim, Talima Pearson, Matthew N. Van Ert, David M. Wagner, Mei Sheng Duh, Amy J. Vogler, Donna L. Maney, Tatum S. Simonson, Jana M. U’Ren and Laura E. DeWald and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.
In The Last Decade
Lynn Huynh
86 papers receiving 1.8k citations
Peers
Lynn Huynh
Robert J. Woods United States
Rachele Cagliani Italy
Leslie J. Parent United States
David J. Hetzel Australia
Paul Giacomin Australia
Mohan S. Maddur India
Michael Cappello United States
Judith A. Smith United States
L. C. Archard United Kingdom
Haiying Liu China
Citations per year, relative to Lynn Huynh Lynn Huynh (= 1×)
peers
Robert J. Woods
Countries citing papers authored by Lynn Huynh
Since
Specialization
Citations
This map shows the geographic impact of Lynn Huynh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynn Huynh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynn Huynh more than expected).
Fields of papers citing papers by Lynn Huynh
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Lynn Huynh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynn Huynh. The network helps show where Lynn Huynh may publish in the future.
Co-authorship network of co-authors of Lynn Huynh
This figure shows the co-authorship network connecting the top 25 collaborators of Lynn Huynh. A scholar is included among the top collaborators of Lynn Huynh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynn Huynh. Lynn Huynh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
O’Donnell, Elizabeth, Nikhil Khandelwal, Lynn Huynh, et al.. (2025). Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma. Blood Advances. 9(15). 3780–3789.
2.
Andritsos, Leslie A., Ali McBride, Derek Tang, et al.. (2024). Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study. Leukemia Research. 148. 107624–107624.
3.
Kovalszki, Anna, Jared Silver, Brian Stone, et al.. (2024). PULMONARY FUNCTION AND ASTHMA CONTROL IN PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS OR HYPEREOSINOPHILIC SYNDROME AND COMORBID ASTHMA TREATED WITH MEPOLIZUMAB. CHEST Journal. 166(4). A28–A45.
4.
Soumerai, Jacob D., Lynn Huynh, Yichuan Grace Hsieh, et al.. (2024). IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence. Blood Advances. 8(16). 4239–4249.
5.
Ball, Brian, et al.. (2024). MDS-059 Real-World Impact of Luspatercept Versus Erythropoiesis-Stimulating Agents (ESAs) on the Healthcare Resource Utilization (HRU) of Patients With Myelodysplastic Syndromes (MDS) in the United States (US). Clinical Lymphoma Myeloma & Leukemia. 24. S385–S385.
6.
Jakes, Rupert W., Namhee Kwon, Lynn Huynh, et al.. (2024). Burden of eosinophilic granulomatosis with polyangiitis in Europe. ERJ Open Research. 10(4). 912–2023.
7.
Karpecki, Paul, et al.. (2023). Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis. BMC Ophthalmology. 23(1). 443–443.
8.
Wong, Raymond, Jesse Fishman, Koo Wilson, et al.. (2023). Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison. Advances in Therapy. 40(4). 1571–1589.
9.
Lin, Kevin, Lynn Huynh, Mohammed Z.H. Farooqui, et al.. (2023). Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.. Journal of Clinical Oncology. 41(16_suppl). e19510–e19510.
10.
Nicolini, Franck‐Emmanuel, et al.. (2023). A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation. Cancers. 15(16). 4161–4161.
11.
Lin, Kevin, Lynn Huynh, Mohammed Z.H. Farooqui, et al.. (2023). Correlation between Real-World Progression-Free Survival (rwPFS) and Overall Survival (OS) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Relapsed or Are Refractory, Intolerant, Resistant to Treatment with a Bruton's Tyrosine Kinase Inhibitor (BTKi). Blood. 142(Supplement 1). 4652–4652.
12.
Wells, J. Connor, Shaan Dudani, Gan Chen, et al.. (2020). Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma. European Urology Open Science. 19. e1105–e1106.
13.
Gounder, Mrinal M., Priscilla Merriam, Ravin Ratan, et al.. (2020). Real‐world outcomes of patients with locally advanced or metastatic epithelioid sarcoma. Cancer. 127(8). 1311–1317.
14.
Metz, David C., Eric Liu, Vijay N. Joish, et al.. (2020). <p>Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome</p>. Cancer Management and Research. Volume 12. 9713–9719.
15.
Green, Courtney, et al.. (2019). Real-World Clinical Burden of Sickle Cell Disease in the US Community-Practice Setting: A Single-Center Experience from the Foundation for Sickle Cell Disease Research. Blood. 134(Supplement_1). 5856–5856.
16.
Wells, J. Connor, Jeffrey Graham, Benoit Beuselinck, et al.. (2019). Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 18(4). e350–e359.
17.
Slater, Jeremy D., Steve Chung, Lynn Huynh, et al.. (2018). Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials. Epilepsy Research. 143. 120–129.
18.
Huynh, Lynn, et al.. (2017). Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR. Journal of Medical Economics. 20(9). 945–951.
19.
Cortes, Jörge E., et al.. (2017). Treatment Characteristics and Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Second-Line Nilotinib or Dasatinib: A Multi-Country Retrospective Chart Review Study. Blood. 130. 2897–2897.
20.
Iorio, Alfonso, et al.. (2014). Indirect Comparison Of The Efficacy Of Recombinant Factor Ix Fc Fusion Protein And Other Factor Ix Products For Prophylaxis: Simulating The Effect Of Compliance On Real-World Effectiveness. Value in Health. 17(3). A230–A230.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Robert J. Woods Breakdown of academic impact, for papers by Rachele Cagliani Breakdown of academic impact, for papers by Leslie J. Parent Breakdown of academic impact, for papers by David J. Hetzel Breakdown of academic impact, for papers by Paul Giacomin Breakdown of academic impact, for papers by Mohan S. Maddur Breakdown of academic impact, for papers by Michael Cappello Breakdown of academic impact, for papers by Judith A. Smith Breakdown of academic impact, for papers by L. C. Archard Breakdown of academic impact, for papers by Haiying Liu